Core Insights - Labcorp Holdings Inc. is focusing on specialty testing areas such as oncology, women's health, autoimmune disease, and neurology to drive growth in upcoming quarters [1] - The company has a solid pipeline of potential acquisitions that align with its financial strategy and will enhance organic growth [1] - Macroeconomic issues and currency fluctuations pose challenges to Labcorp's operations [1] Financial Performance - Labcorp's stock has increased by 4.9% over the past year, contrasting with a 9.2% decline in the industry and a 1.4% decline in the S&P 500 [2] - The company has a market capitalization of $18.70 billion and an earnings yield of 7.2%, outperforming the industry's 6.3% yield [2] - Labcorp delivered an average earnings surprise of 3.2% over the trailing four quarters [2] Growth Drivers - In 2024, Labcorp enhanced its testing capabilities for neurodegenerative diseases with two new blood-based biomarkers [3] - The company expanded its oncology offerings with the Plasma Detect assay, currently in 12 global trials [3] - The Precision Oncology portfolio has seen new strategic service offerings, including FDA-approved diagnostics for gastric cancer and multiple sclerosis monitoring [4] Strategic Acquisitions - Labcorp invested $839 million in acquisitions in 2024 to strengthen its partnerships with hospitals and laboratories [5] - The company acquired assets from Lab Works and Ballad Health to enhance testing services in Alabama and the Appalachian region [5] - In December, Labcorp agreed to acquire assets from MAWD Pathology Group and introduced a new H5 bird flu molecular test in collaboration with the CDC [6] Business Segment Performance - The Biopharma Laboratory Services segment is a key growth driver, with central laboratories showing a 10% revenue increase in Q4 2024 [10] - The Early Development business also demonstrated a 12% year-over-year revenue growth [10] - Labcorp expanded its global molecular bioanalytical capacity with new facilities in Indiana and China [11] Challenges - Labcorp's operations are sensitive to macroeconomic conditions, which have reduced demand for diagnostic testing and drug development services [12] - The company faces currency headwinds due to its significant international exposure, with expected adverse impacts on revenues in 2025 [13] Earnings Estimates - The Zacks Consensus Estimate for Labcorp's 2025 earnings per share is $16.01, with revenues projected at $13.93 billion, indicating a 7.1% improvement from 2024 [14]

Core Insights - Labcorp Holdings, Inc. has launched an FDA-approved HPV self-collection solution and a vaginal swab self-collect option for STI testing, aimed at improving cervical cancer screening rates and empowering individuals in managing their health [1][7]. Company Developments - The new self-collection solutions require a physician's order and can be completed privately at healthcare settings or Labcorp's 2,200 Patient Service Centers nationwide [2]. - Following the announcement, Labcorp's stock experienced a slight decline of 0.04%, closing at $232.65, but the company is addressing barriers to health screenings, which may positively influence market sentiment [3]. - Labcorp has a market capitalization of $19.48 billion, with earnings expected to grow by 9.9% and revenues by 7.1% according to the Zacks Consensus Estimate [4]. Industry Context - The U.S. has over 13,000 annual cervical cancer diagnoses, with approximately 4,000 fatalities, highlighting the importance of HPV testing for early intervention [5]. - The FDA approved self-collection tests for cervical cancer screenings in 2024, providing a less invasive alternative to traditional methods, which may improve screening rates [6]. - The global self-testing market was valued at $11.39 billion in 2024 and is projected to grow at a compound annual growth rate of 8.4% through 2030, driven by personalized healthcare and technological advancements [8]. Strategic Moves - Labcorp announced an agreement to acquire select assets of BioReference Health, focusing on oncology-related clinical testing services across the U.S. [10]. - In the past six months, Labcorp shares have increased by 8.2%, outperforming the industry average rise of 4.8% [11].

Core Viewpoint - Labcorp has launched a new blood-based biomarker test, the pTau-217/Beta Amyloid 42 Ratio, which aids in the diagnosis of Alzheimer's disease and meets performance criteria for confirming amyloid pathology consistent with the disease [1][2]. Group 1: Test Features and Benefits - The pTau-217/Beta Amyloid 42 Ratio test provides results comparable to positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing, supporting neurologists and dementia specialists in diagnosing Alzheimer's disease [2]. - This test has a sensitivity and specificity of 95%, which is substantially equivalent to the performance of amyloid PET imaging and CSF testing [8]. - Blood draws for the test can be conducted in a physician's office or at any of Labcorp's over 2,000 Patient Service Centers (PSCs) nationwide, making it more accessible [8]. Group 2: Market Context and Impact - An estimated 6.9 million Americans are currently living with Alzheimer's disease, a figure projected to nearly double by 2050, highlighting the growing need for effective diagnostic tools [3]. - The average time from the onset of symptoms to diagnosis is approximately 2.8 years, indicating a significant delay in the current diagnostic process [3]. - The introduction of this test aims to reduce the time and anxiety associated with diagnosing Alzheimer's disease, enabling more timely and informed treatment decisions for patients and their families [4]. Group 3: Company Overview - Labcorp is a global leader in laboratory services, providing insights and advancing science to improve health through diagnostics and drug development capabilities [7]. - The company employs nearly 70,000 individuals and serves clients in approximately 100 countries, supporting over 75% of new drugs approved by the FDA in 2024 [7].

Core Viewpoint - Labcorp is expanding its offerings to include FDA-approved self-collection solutions for HPV and STI testing, aiming to improve access to cervical cancer screenings and sexually transmitted infection tests [1][4][5] Group 1: Cervical Cancer Screening - Each year, over 13,000 women in the U.S. are diagnosed with cervical cancer, with approximately 4,000 deaths from this preventable disease [3] - HPV testing is essential for early intervention and treatment, yet one in four women of screening age were not up to date with cervical cancer screening recommendations in 2021 [3] - The FDA approved self-collection tests for cervical cancer screenings in 2024, providing a less invasive alternative to traditional Pap smears [4][5] Group 2: STI Testing - Labcorp will offer a vaginal swab self-collect option for STI testing, including chlamydia, gonorrhea, trichomonas, and mycoplasma genitalium [5] - In 2023, the CDC reported 2.4 million cases of STIs diagnosed and reported, highlighting the need for early detection to minimize long-term effects [5] - Self-collection for STI testing can empower individuals to take control of their sexual health and expedite the diagnosis-to-treatment timeline [6] Group 3: Accessibility and Convenience - The self-collection options will be available starting April 7, allowing patients to complete tests privately in healthcare settings or at Labcorp's 2,200 Patient Service Centers nationwide [7][9] - Results from the tests will be sent electronically to both the ordering physician and the patient via their Labcorp Patient account [9]

About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new d ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Sco ...

Labcorp Holdings Inc. (LH) , or Labcorp, is prioritizing key specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, aiming to tap into strong growth opportunities.  The company maintains a solid pipeline of potential acquisitions that fits its financial strategy and will enhance its organic growth. Strong financial stability also bodes well for the stock. Meanwhile, macroeconomic volatilities and adverse currency fluctuations may dent its growth.In the past year, this Z ...

Revenue and Growth - For the year ended December 31, 2024, the Company's revenues were $13,008.9 million, a 7.0% increase from $12,161.6 million in 2023, driven by organic revenue growth of 3.9% and acquisitions contributing 2.8%[304] - The Dx segment revenues increased by 7.7% to $10,144.3 million, with organic revenue growth of 4.1% and acquisitions contributing 3.7%[309] - The BLS segment revenues rose by 5.3% to $2,922.6 million, primarily due to organic growth of 4.3% and favorable foreign currency translation of 1.1%[311] - The Company expects continued growth driven by organic demand and strategic acquisitions, with a focus on enhancing operational efficiency[306] Expenses and Costs - Cost of revenues increased by 6.7% to $9,384.5 million, while the cost of revenues as a percentage of revenues decreased to 72.1% from 72.3%[312] - Selling, general and administrative expenses rose by 10.3% to $2,230.0 million, with SG&A as a percentage of revenues increasing to 17.1% from 16.6%[313] - The Company recorded net restructuring charges of $46.0 million for 2024, a decrease of 6.3% compared to $49.1 million in 2023[316] Income and Cash Flow - Operating income for the Company increased by 49.8% to $1,086.7 million, with segment operating income rising to $2,065.2 million, a 3.9% increase[323] - Net cash provided by continuing operating activities was $1,585.8 million, up from $1,202.3 million in 2023, reflecting higher cash earnings[329] - Cash and cash equivalents at December 31, 2024, totaled $1,518.7 million, compared to $536.8 million in 2023[328] Capital Expenditures and Financing - Capital expenditures for 2024 were $489.9 million, representing 3.8% of revenues, primarily for growth projects in core businesses[331] - Net cash provided by continuing financing activities for 2024 was $779.9 million, a significant improvement from cash used of $1,559.0 million in 2023, driven by $2,000.0 million in new debt securities[332] - The Company issued $2,000.0 million in debt securities, including $650.0 million of 4.35% senior notes due 2030, with net proceeds of approximately $1,983.0 million used for debt repayment and general corporate purposes[333] Shareholder Returns and Debt - The Company authorized a new share repurchase plan for up to $1,000.0 million, with a total authorization of $1,280.4 million remaining as of December 31, 2024[339] - The Company paid $243.1 million in dividends for 2024 and announced a cash dividend of $0.72 per share for Q1 2025, totaling approximately $61.0 million[340] - Total future payments for debt instruments as of December 31, 2024, amounted to $6,373.9 million, with $1,000.4 million due within 12 months[346] Foreign Currency and Risk Management - Approximately 13.7% of the Company's revenues for the year ended December 31, 2024, were denominated in currencies other than the U.S. dollar (USD) compared to 12.9% in 2023[381] - A hypothetical change of 10% in average exchange rates would have impacted income before income taxes for 2024 by approximately $27.4 million[381] - The Company limits foreign currency transaction risk through exchange rate fluctuation provisions in contracts or hedging with foreign currency forward contracts[382] - The Company manages interest rate risk through a mix of fixed and variable rate debt, including the use of interest rate swaps[384] Financial Instruments and Accounting - The Company had 12 open foreign exchange forward contracts with a notional value totaling approximately $302.4 million as of December 31, 2024[382] - The Company is a party to USD to Swiss Franc cross-currency swap agreements with an aggregate notional amount of $1,200.0 million[383] - The Company accounts for business combinations under the acquisition method, recording acquired assets at their estimated fair values as of the acquisition date[365] - The Company assesses goodwill and indefinite-lived intangible assets for impairment at least annually, with the most recent assessment indicating fair values greater than carrying values[373] - Deferred tax assets and liabilities are recognized for future tax consequences, measured using enacted tax rates expected to apply to taxable income[366] - The Company entered into fixed-to-variable interest rate swap agreements for its 2.70% senior notes due 2031 with an aggregate notional value of $500.0 million[386] - The variable interest rates are based on three-month LIBOR, which transitioned to SOFR in 2023, plus 1.0706%[386]

Core Insights - Labcorp has launched Labcorp® Plasma Complete™, a ctDNA-based genomic profiling solution for advanced solid tumors, enabling oncologists to make personalized treatment decisions from a simple blood draw [1][2]. Group 1: Product Features - Labcorp Plasma Complete detects genomic alterations in ctDNA across 521 genes, including single nucleotide variants (SNVs), insertions/deletions (InDels), amplifications, translocations, and microsatellite instability [2]. - The test provides a reportable range with a variant allele frequency as low as 0.1% and a specificity greater than 99.99%, allowing for precise detection of tumor-specific biomarkers [4]. Group 2: Clinical Application - The solution is designed to guide targeted treatment decisions, especially when tissue-based testing is not feasible, thus expanding Labcorp's oncology portfolio [2][3]. - Labcorp Plasma Complete is validated in a CAP-accredited and CLIA-certified laboratory, ensuring clinical accuracy and reliability [4]. Group 3: Support for Oncologists - The test simplifies the interpretation of complex genomic data through clear and comprehensive clinical reports, reducing the burden on oncologists [3]. - Integration with Labcorp's broad cancer diagnostic portfolio aids in guiding treatment decisions across all stages of cancer care [3]. Group 4: Research and Development - Labcorp Plasma Complete remains available for biopharmaceutical research, in addition to its clinical applications [4]. - The company has supported over 75% of new drugs and therapeutic products approved by the FDA in 2024, showcasing its significant role in drug development [5].

Core Insights - The article does not provide specific insights into any companies or industries, focusing instead on the author's personal disclosures and lack of investment positions [1][2] Group 1 - The author has no stock, option, or similar derivative positions in any of the companies mentioned [1] - There are no plans to initiate any such positions within the next 72 hours [1] - The article expresses the author's own opinions and is not influenced by compensation from any company [1] Group 2 - Seeking Alpha clarifies that past performance is not a guarantee of future results [2] - No specific investment recommendations or advice are provided for individual investors [2] - The views expressed may not reflect those of Seeking Alpha as a whole [2]